To investigate sociodemographic factors influencing decision of initially active surveillance (AS) prostate cancer (PCa) patients to opt for definitive therapy, and, specifically, choice of radical prostatectomy (RP) versus radiation therapy (XRT).
Contactin 1 (CNTN1) is a new oncogenic protein of prostate cancer (PC); its impact on PC remains incompletely understood. We observed CNTN1 upregulation in LNCaP cell-derived castration-resistant PCs (CRPC) and CNTN1-mediated enhancement of LNCaP cell proliferation.
(UroToday.com) There has been a rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in nmCRPC at GU ASCO in February 2018, there were no specifically approved treatment options for […]
(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. Prior to the publication of TAX-327, there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen […]
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, there […]
(UroToday.com) Members of the forkhead transcription factor (FOX) family are important mediators of embryonic development and are known to be altered in a variety of cancers. However, to date, the functional role of FOXF1 in bladder tumorigenesis and progression has not been clearly characterized. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. […]
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
(UroToday.com) Nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitor combinations are now standard of care first-line treatment options for metastatic renal cell carcinoma (mRCC). However, there is limited head-to-head comparative evidence between these strategies in this evolving treatment landscape in mRCC:
(UroToday.com) First-line pembrolizumab monotherapy, although not standard of care, has demonstrated efficacy in clear cell renal cell carcinoma (RCC). Previously, the first-line KEYNOTE-427 study demonstrated an overall response rate of 34%, and a median progression-free survival of 7.1 months. Stereotactic ablative body radiotherapy is an option for oligometastatic clear cell RCC, but patients often develop distant […]
(UroToday.com) With the emergence of multiple active treatment options in renal cell carcinoma (RCC), predictive biomarkers for optimal treatment selection are lacking. Gene expression data from IMmotion1511 and Javelin Renal 1012 clinical trials generated anti-angiogenic and immune signatures that warrant further validation. At the Poster Highlights: Renal Cell Cancer – Gene Signatures Session at the 2021 […]
